Skip to main content

Table 2 Summary of treatment 42 days treatment outcomes based on PP analysis among patients who treated Pyramax at Hamusit Health Centre, Northwest Ethiopia, 2021

From: Therapeutic efficacy of pyronaridine-artesunate (Pyramax®) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia

Treatment outcomes

Frequency (%)

ETF

0 (0)

LCF

0 (0)

LPF

2/90 (2.3%)

TTF

2/90 (2.3%)

ACPR

86/87 (98.9%)

LFU

2/90 (2.2%)

Withdrawal

0 (0)

  1. ACPR Adequate clinical and parasitological response, ETF Early treatment failure, LCF Late clinical failure, LFU Lost follow up, LPF Late parasitological failure, N number, TTF Total treatment failure